<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, March 28, 2019 (HealthDay News) — Adding docetaxel-based chemotherapy (CT) to standard treatment for high-risk nonmetastatic prostate cancer improves survival, according to a study published online March 12 in the Journal of Clinical Oncology<\/i>.<\/p>\n
Seth A. Rosenthal, M.D., from Sutter Cancer Centers in Sacramento, California, and colleagues assessed whether docetaxel CT could improve overall survival and clinical outcomes among patients with high-risk nonmetastatic prostate cancer. A total of 563 patients were randomly assigned to receive standard long-term androgen suppression (AS) plus radiotherapy (RT) with or without adjuvant CT.<\/p>\n
The researchers found that during a median follow-up of 5.7 years, the four-year overall survival rate was 89 percent for AS + RT and 93 percent for AS + RT + CT (hazard ratio [HR], 0.69). There were fewer deaths resulting from prostate cancer in the AS + RT + CT arm versus AS + RT (23 versus 16 deaths). The six-year rate of distant metastasis was lower for AS + RT + CT versus AS + RT (9.1 versus 14 percent; HR, 0.6), and the six-year disease-free survival rate was higher for AS + RT + CT (65 versus 55 percent for AS + RT; HR, 0.76).<\/p>\n
“The trial suggests that docetaxel CT may be an option to be discussed with selected men with high-risk prostate cancer,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which partially funded the study.<\/p>\n